MedTrace Logo

Lentivirus Transduced Acute Myeloid Leukaemia Blasts Expressing B7.1 (CD80) and IL-2

NCT00718250 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2008-07-18

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and tolerability of an 'AML Cell Vaccine' in patients with poor prognosis acute myeloid leukaemia (AML).

Conditions

  • Leukemia, Myeloid, Acute

Interventions

BIOLOGICAL

RFUSIN2-AML1

AML cell vaccine alone. x4 doses 3 weeks apart

BIOLOGICAL

Donor leukocyte infusion (DLI)

1 dose 1x107/kg

BIOLOGICAL

RFUSIN2-AML1 and donor leukocyte infusion

AML cell vaccine x 4 doses 3 weeks apart Donor leukocyte infusion 1x107/kg x 1 dose

BIOLOGICAL

RFUSIN2-AML1 and donor leukocyte infusion

AML cell vaccine x4 doses 3 weeks apart Donor leukocyte infusion 1x108/kg x1 dose

Sponsors & Collaborators

  • Department of Health

    collaborator AMBIG

  • Leukemia Research Fund

    collaborator OTHER

  • Elimination of Leukaemia Fund

    collaborator OTHER

  • King's College Hospital NHS Trust

    lead OTHER

Principal Investigators

  • Ghulam J Mufti · King's College London, London, United Kingdom

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2011-05-31
Completion
2012-02-29

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00718250 on ClinicalTrials.gov